A Randomized, Partially-Blinded, Placebo-Controlled, Two-Way Crossover, Proof of Concept Study to Compare the Relative Efficacy of CRTh2 Receptor Antagonist, QAV680 Against Placebo in the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model.
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2010
At a glance
- Drugs Mometasone; QAV 680
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- 18 Feb 2009 New trial record